To further validate the role of mutant p53 in the response to AF and olaparib, both compounds were validated in NSCLC knock-in (NCI-H1299 Null, p53 R175H mutant vs. p53 R273H mutant) and NSCLC knock-down (NCI-H2228 NTC vs. TP53 shRNA 1–3) cell panels of mutant p53 (Figure 1C–H). This evidence concerns the gene TP53 and non-small cell lung carcinoma.